BFC Planning’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-173
Closed -$5.44K – 3492
2026
Q2
$5.44K Hold
173
– – ﹤0.01% 2641
2026
Q1
$4.28K Hold
173
– – ﹤0.01% 2364
2025
Q4
$4.04K Hold
173
– – ﹤0.01% 2430
2025
Q3
$3.41K Buy
+173
New +$3.56K ﹤0.01% 2319
2025
Q2
– Sell
-13,090
Closed -$317K – 2705
2025
Q1
$317K Buy
13,090
+1,202
+10% +$27.1K 0.03% 452
2024
Q4
$248K Buy
+11,888
New +$255K 0.02% 530

Other funds holding CPRX

BFC Planning's CPRX Position: Q3 2026 in Review

BFC Planning sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 173 shares — an estimated $5.44K sold.

BFC Planning first reported a position in CPRX in Q4 2024 and held it in 6 quarters. The position peaked at $317K in Q1 2025. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.

  • BFC Planning reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
  • BFC Planning sold 173 Catalyst Pharmaceutical shares in Q3 2026, an estimated $5.44K.
  • BFC Planning first reported a position in Catalyst Pharmaceutical in Q4 2024 and held it in 6 quarters.
  • BFC Planning's Catalyst Pharmaceutical position peaked at $317K in Q1 2025.
  • 2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.